Copyright
©The Author(s) 2016.
World J Gastroenterol. Dec 28, 2016; 22(48): 10631-10642
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10631
Published online Dec 28, 2016. doi: 10.3748/wjg.v22.i48.10631
Table 2 Irritable bowel syndrome symptom characteristics n (%)
| Placebo (n = 131) | Low-dose (n = 129) | High-dose (n = 131) | |
| IBS subtype | |||
| IBS-C | 25 (19.1) | 20 (15.5) | 20 (15.3) |
| IBS-D | 49 (37.4) | 51 (39.5) | 52 (39.7) |
| IBS-M | 56 (42.7) | 58 (45.0) | 58 (44.3) |
| IBS-U | 1 (0.8) | 0 (0.0) | 1 (0.8) |
| Postinfectious IBS | 9 (6.9) | 4 (3.1) | 7 (5.3) |
| Psychological comorbidities | 9 (6.9) | 6 (4.7) | 13 (9.9) |
| Symptoms provoked by specific food | 103 (79.8)1 | 116 (89.9) | 120 (91.6) |
| Family history of intestinal disorders or diseases | 95 (72.5) | 97 (75.2) | 92 (70.8)2 |
- Citation: Lyra A, Hillilä M, Huttunen T, Männikkö S, Taalikka M, Tennilä J, Tarpila A, Lahtinen S, Ouwehand AC, Veijola L. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World J Gastroenterol 2016; 22(48): 10631-10642
- URL: https://www.wjgnet.com/1007-9327/full/v22/i48/10631.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i48.10631